Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2022-12-19 00:00:00 ET · period of report 2022-12-15 · accession 0000899243-22-039056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +1,597 | 1,297 | New | +$36.8K |
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $28.37 | -1,597 | 0 | -100% | -$45.3K |
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $0.00 | -1,597 | 62.9K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-15 | M | A | 300 | $23.03 | 300 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-15 | S | D | 300 | $28.08 | 0 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-12-16 | M | A | 1,297 | $23.03 | 1,297 | D | — | — | |
| 4 | Common | Common Stock | 2022-12-16 | S | D | 1,297 | $28.44 | 0 | D | — | — | (F2) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-12-16 | M | D | 1,297 | $0.00 | 61,647 | D | $23.03 · — to 2031-09-22 | 1,297 Common Stock | (F3) The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-12-15 | M | D | 300 | $0.00 | 62,944 | D | $23.03 · — to 2031-09-22 | 300 Common Stock | (F3) The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |